news

BenevolentAI becomes first AI company to appoint a Chief Medical Officer

BenevolentAI is the first AI company to have a CMO on its staff.

The British artificial intelligence company BenevolentAI has appointed Dr Patrick Keohane as Chief Medical Officer.  

Dr Patrick Keohane

AI in bioscience

Patrick will take up the position of CMO of BenevolentBio – a subsidiary of BenevolentAI that applies its unique and disruptive AI technology to accelerate a pipeline of better medicines for patients and to explore further applications for AI in bioscience.  He will work with BenevolentBio’s expanding team of experienced drug discovery scientists, technology experts, and bioscience researchers to rapidly identify and progress novel therapies into early and late stage clinical trials.

Dr Keohane

With over 20 years of experience, Dr Keohane trained as a Gastroenterologist in the NHS and worked for the Medical Research Council. He has held senior management positions in Research and Development at Eli Lilly and AstraZeneca, and has worked in the US, Japan and Europe. He joins the Company from Glenmark Pharmaceuticals, where he held the position of Chief Medical Officer.

BenevolentAI

BenevolentAI is a British technology company harnessing the power of AI to enhance and accelerate scientific discovery and innovation.  The Company was founded to explore the application of AI in the field of bioscience and has since diversified its technology for applications across many scientific industries. BenevolentAI’s focus is applying AI where the partnership between scientist and technology can create new discoveries that benefit society and address some of the world’s most pressing challenges.

BenevolentBio, a subsidiary of BenevolentAI, focuses on turning the world’s mass of highly fragmented biomedical knowledge and pharmaceutical R&D data into useable new information and insight.  This validated technology has significantly accelerated the process of drug discovery and development in order to bring new medicines to patients more efficiently.

Professor Jackie Hunter, CEO of BenevolentBio commented, “Patrick’s appointment fits perfectly with our ethos of integrating scientific expertise and technology to revolutionise the drug development process. He brings extensive experience in the worldwide development of medicines and will play a key part in the development of our strong clinical pipeline.

Send this to a friend